Evosep receives strategic investment from Novo Holding A/S to accelerate its effort on clinical proteomics

Glass laboratory flasks on light table

Evosep today announced that Novo Holdings A/S has become a minority shareholder in Evosep Aps with a US$ 40m investment to further Evosep’s technology and application portfolio for clinical proteomics.

Using machine learning models to guide the design of long-acting injectable drug formulations

Previous article

Deciphering disease progression and cell processes with TIGER, in vivo and non-invasively

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News